These patients all had non-muscle invasive tumors that did not respond to BCG. A single dose of 366-821 MBq of Bi-213-EGFR-Mab was administered directly into the bladder by catheter. The bladder was drained 2 hours after injection.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
A follow-on study is planned with higher doses and repeat treatments.
Presented By: Klemens Scheidhauer from Department of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.